Johnson & Johnson (NYSE: JNJ) announced it will present 24 abstracts featuring clinical data and real-world evidence across its neuropsychiatry portfolio at the 2026 Psych Congress Annual Meeting, scheduled for September 15-19 in New Orleans, Louisiana.

Among the presentations will be pivotal Phase 3 data evaluating the efficacy and safety of Caplyta (lumateperone) in bipolar mania — described in the company's press release as the first presentation of such data. Caplyta is currently approved for major depressive disorder, schizophrenia, and bipolar depression, but is not approved for bipolar mania. Additional Caplyta data across bipolar depression and major depressive disorder (MDD) will also be presented.

The company will also present new analyses on Spravato (esketamine) nasal spray examining its effect on anhedonia — a core symptom of depression — based on real-world evidence. Phase 3 clinical data for seltorexant, an investigational therapy being studied as an adjunctive treatment for MDD with insomnia symptoms, will be included as well.

Additional presentations will cover real-world studies on schizophrenia-related hospitalizations in young dual-eligible patients prior to initiation of long-acting injectable antipsychotics, as well as treatment satisfaction data for Johnson & Johnson's paliperidone palmitate injectable portfolio, which includes Invega Sustenna, Invega Trinza, and Invega Hafyera.

"People living with neuropsychiatric disorders often face complex, overlapping symptoms that can make identification, treatment selection and long-term management especially challenging," said Jane Tiller, MD, Vice President, Global Head of Development, Neuroscience, Johnson & Johnson.

Seltorexant remains investigational and has not received regulatory approval. The U.S. Food and Drug Administration recently approved a supplemental New Drug Application for Caplyta with long-term data supporting reduced risk of relapse in schizophrenia.